We are live on ! Find out more
DMAC icon

DiaMedica Therapeutics
DMAC

16 hedge funds and large institutions have $6.37M invested in DiaMedica Therapeutics in 2019 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

167% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 3

50% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 2

45% more funds holding

Funds holding: 11 → 16 (+5)

38% more capital invested

Capital invested by funds: $4.6M → $6.37M (+$1.77M)

2.26% more ownership

Funds ownership: 8.47% → 10.73% (+2.3%)

Holders
16
Holders Change
+5
Holders Change %
+45.45%
% of All Funds
0.35%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
3
Reduced
2
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
GPCM
Granite Point Capital Management
Massachusetts
+$795K
2
MHP
Manatuck Hill Partners
Connecticut
+$400K
3
Millennium Management
Millennium Management
New York
+$344K
4
Goldman Sachs
Goldman Sachs
New York
+$177K
5
EVC
Eidelman Virant Capital
Missouri
+$121K

Top Sellers

Rank Fund Capital Flow
1
SCM
Stonepine Capital Management
Oregon
-$1.14M
2
WC
Wexford Capital
Florida
-$259K
3
CHP
Cable Hill Partners
Oregon
-$5K
4
PFGIA
Patriot Financial Group Insurance Agency
Massachusetts
-$3.46K
Name Holding Trade Value Shares
Change 		Change in
Stake
WC
1
Wexford Capital
Florida
$1.98M -$259K -75,000 -16%
MHP
2
Manatuck Hill Partners
Connecticut
$1.33M +$400K +115,800 +76%
GPCM
3
Granite Point Capital Management
Massachusetts
$1.14M +$795K +229,970 New
WVP
4
Worth Venture Partners
New Jersey
$657K +$43.7K +12,651 +11%
Millennium Management
5
Millennium Management
New York
$493K +$344K +99,340 New
Goldman Sachs
6
Goldman Sachs
New York
$253K +$177K +51,061 New
EVC
7
Eidelman Virant Capital
Missouri
$173K +$121K +35,000 New
Vanguard Group
8
Vanguard Group
Pennsylvania
$170K +$118K +34,238 New
BlackRock
9
BlackRock
New York
$134K +$57.6K +16,651 +160%
UBS Group
10
UBS Group
Switzerland
$11K +$7.78K +2,250 New
PFGIA
11
Patriot Financial Group Insurance Agency
Massachusetts
$10K -$3.46K -1,000 -33%
Royal Bank of Canada
12
Royal Bank of Canada
Ontario, Canada
$10K – – –
Bank of Montreal
13
Bank of Montreal
Ontario, Canada
$2K – – –
FIA
14
FNY Investment Advisers
New York
$2K +$1.8K +521 New
GCM
15
Gables Capital Management
Florida
$1K – – –
SCM
16
Stonepine Capital Management
Oregon
– -$1.14M -250,000 Closed
CHP
17
Cable Hill Partners
Oregon
– -$5K -1,000 Closed
Toronto Dominion Bank
18
Toronto Dominion Bank
Ontario, Canada
– +$166 +48 New

DMAC Hedge Fund Activity: Q2 2019 in Review

16 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in DiaMedica Therapeutics (DMAC) for Q2 2019, worth a combined $6.37M — up 38% from $4.6M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new DMAC positions and 3 closed out — a net gain of 5 holders — while 3 added to existing stakes and 2 trimmed.

The largest buyer was Granite Point Capital Management, opening a new position worth an estimated $795K. The largest seller was Stonepine Capital Management, exiting entirely with an estimated $1.14M sold.

  • 16 institutional investors held DiaMedica Therapeutics (DMAC) as of Q2 2019, up from 11 in Q1 2019.
  • Funds reported $6.37M of DiaMedica Therapeutics stock for Q2 2019, up 38% quarter-over-quarter.
  • 8 funds opened new DiaMedica Therapeutics positions in Q2 2019 and 3 closed out, a net change of +5 holders.
  • The largest DiaMedica Therapeutics buyer in Q2 2019 was Granite Point Capital Management, an estimated $795K added.
  • The largest DiaMedica Therapeutics seller in Q2 2019 was Stonepine Capital Management, an estimated $1.14M sold.

Based on aggregated 13F filings for Q2 2019.